プロジェクト概要

プロジェクト概要

概要

SinglePass is a medical device company developing a portable, single-use electrocautery system designed to cauterize and seal biopsy tracts following percutaneous tissue sampling. The company’s flagship device, Kronos, is intended to reduce post-biopsy bleeding and enable safer, more efficient procedural workflows. I’m an investor in SinglePass and serve on the advisory board.

なぜ重要なのか

Post-biopsy bleeding remains a meaningful clinical and operational issue—particularly in renal biopsies, where bleeding risk can drive prolonged observation, delayed discharge, and downstream complications. A tract-closure approach that integrates cleanly into existing workflows has the potential to reduce bleeding risk, shorten recovery time, and support earlier discharge without adding procedural complexity.

技術と製品のハイライト

  • Tract closure at the source: Kronos is designed to cauterize the biopsy tract through the coaxial needle path immediately after sampling.

  • Portable, single-use design: Battery-powered and self-contained, with an intuitive user interface that fits naturally into image-guided biopsy workflows.

  • Workflow-friendly: Does not require capital equipment or complex setup, supporting adoption in hospital and outpatient settings.

  • Clinically accessible pricing: Designed to be practical for routine use rather than reserved for edge cases.

  • Expanding applications: While particularly compelling for renal biopsies, the platform is being evaluated for broader procedural use cases.

Team & Execution

SinglePass is led by an experienced and highly capable team. I’ve worked directly with John Zehren, CEO & Board Member, and Steve Fried, Head of Commercial Excellence—both bring deep operational and commercialization experience. Meera Shier, SVP of Marketing, leads go-to-market strategy with clarity and discipline. The broader team reflects strong execution culture across engineering, clinical, and commercial functions.

プロフェッショナルな展望

Image-guided biopsy volumes remain large and durable across oncology, nephrology, hepatology, and interventional radiology. Devices that reduce complications and post-procedure resource utilization—without disrupting standard technique—are well positioned for adoption. SinglePass is addressing a concrete procedural pain point with a focused, pragmatic solution.

結論

SinglePass is building a tract-closure platform aimed at improving safety and efficiency in percutaneous biopsy. The combination of a thoughtfully designed device, a strong leadership team, and a clear clinical rationale makes this a compelling solution for real-world procedural care.